Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday

Dogwood Therapeutics (NASDAQ:DWTX) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 23, 2026 at 8:00 AM ET.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.96. On average, analysts expect Dogwood Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dogwood Therapeutics Price Performance

NASDAQ:DWTX opened at $1.98 on Friday. The firm has a market cap of $66.13 million, a price-to-earnings ratio of -0.10 and a beta of 1.90. The firm’s fifty day moving average price is $2.91 and its 200 day moving average price is $4.57. Dogwood Therapeutics has a 1-year low of $1.94 and a 1-year high of $9.50.

Wall Street Analysts Forecast Growth

DWTX has been the subject of several research analyst reports. Wall Street Zen downgraded Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research report on Friday, February 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.00.

Institutional Trading of Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is currently owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.